TScan Therapeutics, Inc. - TCRX STOCK NEWS

TScan Therapeutics (TCRX) announced its Q1 2022 financial results, reporting revenue of $3 million, up from $2 million YoY, attributed to its collaboration with Novartis. The company ended the quarter with $140.8 million in cash, sufficient to fund operations into 2024. TScan is set to initiate its Phase 1 umbrella trial for leukemia therapies TSC-100 and TSC-101 in Q2 2022, despite receiving a clinical hold on TSC-101 from the FDA. Future milestones include presenting clinical data by year-end and advancing its solid tumor TCR therapy candidates.

TScan Therapeutics, Inc. (Nasdaq: TCRX) announced it will host a virtual KOL event on May 19, 2022, at 4:30 p.m. ET, discussing key presentations from the ASGCT Annual Meeting held from May 16-19, 2022. Three abstracts were accepted, focusing on innovative TCR-T cell therapies, including TSC-200-A02 for HPV-positive tumors, multiplexed therapies for solid tumors, and a novel TCR-T candidate for head and neck cancer. The company aims to advance its TCR-T candidates, which target multiple antigens to enhance cancer treatment efficacy.

TScan Therapeutics, Inc. (TCRX) has appointed Leiden Dworak, CPA, MBA, as Vice President of Finance, enhancing its financial infrastructure amid clinical advancements. Dworak brings over ten years of financial expertise from roles at AVROBIO and Moderna. His financial planning experience is expected to aid TScan in achieving key development milestones as they progress with their T cell receptor therapies for cancer. TScan is strategically advancing its lead liquid tumor therapies, aiming to prevent relapse post-hematopoietic stem cell transplantation.

TScan Therapeutics (TCRX) has received FDA clearance for its IND application for TSC-100, targeting hematologic malignancies. The Phase 1 trial for its liquid tumor program is set to start in H1 2022, with preliminary data expected in H2 2022. The company anticipates two additional INDs for the TSC-200 series by year-end. As of December 31, 2021, TScan reported cash and equivalents of $161.4 million, which is projected to fund operations into 2024. Revenue surged to $10.1 million for 2021 compared to $1.1 million in 2020, despite a net loss of $48.6 million.

TScan Therapeutics, Inc. (Nasdaq: TCRX) has announced its participation in two major investor conferences. The Cowen 42nd Annual Health Care Conference will feature a virtual discussion on March 9, 2022, at 9:10 a.m. ET. Subsequently, TScan will participate in the Barclays Global Healthcare Conference with a fireside chat on March 16, 2022, at 8:30 a.m. ET in Miami Beach, FL. Webcasts of both sessions will be available on TScan's website, with archived replays accessible for 30 days post-event.

TScan Therapeutics (Nasdaq: TCRX) will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 12:00 p.m. ET. The presentation will focus on the company’s T-cell receptor (TCR) engineered therapies for cancer treatment, including lead candidates TSC-100 and TSC-101, targeting hematologic malignancies. A webcast of the event will be accessible via the company’s website and will remain available for 60 days post-event.

TScan Therapeutics (Nasdaq: TCRX) has received FDA clearance for its investigational new drug (IND) application for TSC-100, targeting hematologic malignancies. The Phase 1 trial is set to begin in the first half of 2022. However, the IND for TSC-101 is on hold due to concerns about off-tumor reactivity. The company aims to evaluate TSC-100 against standard care in allogeneic hematopoietic cell transplantation patients, with preliminary results expected later in 2022. This milestone underscores TScan's focus on T-cell receptor engineered therapies for cancer treatment.

TScan Therapeutics (TCRX) announced the completion of IND submissions for its lead TCR-T candidates, TSC-100 and TSC-101, targeting leukemia relapse post-transplant. The company has ambitious plans for 2022, anticipating Phase 1 trials for these therapies in the first half, with preliminary results expected by the latter half of the year. TScan is also advancing its solid tumor programs, including targets like HPV16, and is positioned for strong growth with a cash reserve of $182.9 million expected to fund operations into 2024.

TScan Therapeutics (TCRX) announced significant advancements in its liquid tumor candidates TSC-100 and TSC-101 at the ASH Annual Meeting. These T-cell receptor therapies aim to address hematologic malignancies and prevent relapse post-hematopoietic cell transplant. The company plans to file investigational new drug applications for both therapies by the end of 2021. A Phase 1 clinical trial is expected to commence in H1 2021. TScan will host a virtual KOL event on December 15, 2021, to discuss the posters and clinical trial design.